Enolic Acid Oxicam Preferential COX-2 Inhibitor • Rx

Meloxicam

Brand Reference: Mobic

Medically Reviewed by Dr. Devon Caldwell, DO, MPH (NPI #1568063758)
85.40%
Patient “Worth It”
31 verified logs
$4.70
Lowest Monthly Cash

Meloxicam Clinical & Real-World Cost Fact Matrix

Metric Verified Benchmark Source
Meloxicam RxNorm Concept ID 41493 U.S. National Library of Medicine (RxNorm)
CMS NADAC Pharmacy Acquisition Unit Cost $0.0250 / unit CMS Medicaid NADAC Weekly Feed
Walk-In Chain Pharmacy Cash Average $19.00 / mo CMS NADAC + U.S. Retail Markup Index
Mark Cuban Cost Plus Wholesale Price $4.70 / mo Cost Plus Drugs Wholesale Feed
Community Mean Out-of-Pocket Paid $5.50 / mo 31 Zero-PHI Verified Patient Logs
INSTANT PRESCRIPTION & CASH ROUTING

Verified Online Prescribers & Wholesale Pharmacies for Meloxicam

DotMD Club Members get $29 flat-rate script renewals →
Mark Cuban Cost Plus Drugs (Wholesale Pharmacy)
Requires an existing doctor prescription. Need a script? Pair with a $29 DotMD Club TeleMed consult.
$4.70/mo
Wholesale Cash Price
View Wholesale Rx →
AgelessRx Geroprotective Telehealth (Online Doctor Consult + Delivery)
Asynchronous physician review included • Ships in ~3 days • Rx included in monthly tier
$ 65.00
All-In Monthly
Start Online Visit →

Meloxicam Clinical Pharmacology & DailyMed Monograph

RxCUI 41493 • NDC 00378-1089-01

Preferentially inhibits inducible COX-2 over COX-1 across a full 20-hour plasma half-life, delivering 24-hour once-daily osteoarthritis and tendinopathy anti-inflammatory coverage.

CMS National Average Drug Acquisition Cost (NADAC) tracking places Meloxicam (Mobic, RxCUI 41493) at $0.0250 per unit, whereas walk-in chain pharmacies bill cash patients an average of $19.00 monthly—creating a 75% ($14.30/mo) wholesale arbitrage spread down to $4.70.

Systemic exposure to Meloxicam reflects 89% oral absorption kinetics and hepatic cyp2c9 (major) and minor cyp3a4 oxidation to four inactive metabolites, sustaining receptor engagement across a 15–20 hours half-life window (2–4 hours peak synovial distribution response profile).

Dosing protocols (7.5 mg PO once daily or 15 mg PO once daily max) balance efficacy (85.40% patient satisfaction across 31 logs) against mild epigastric fullness (11% of reports), edema (6% of reports), with strict avoidance in cabg surgery; active peptic ulceration; egfr < 30 ml/min.

Half-Life
15–20 hours
Bioavailability
89% oral
Metabolism & Clearance
Hepatic CYP2C9 (major) and minor CYP3A4 oxidation to four inactive metabolites
Clinical Onset
2–4 hours peak synovial distribution

Standard Adult Titration & Dosages

7.5 mg PO once daily 15 mg PO once daily max

Absolute & Relative Contraindications

  • CABG surgery
  • Active peptic ulceration
  • eGFR < 30 mL/min

Logged Side-Effect Incidence (31 Reports)

Mild epigastric fullness 11%
Edema 6%

Meloxicam Patient Dosage Logs & Out-of-Pocket Cost Ledger

Across 31 verified cash-pay logs, Meloxicam achieves a 85.40% Worth-It rating with out-of-pocket spend averaging $5.50/mo versus $19.00/mo walk-in retail.

15-Second Anonymous Micro-Log (Zero-PHI Architecture)

Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.

Effectiveness: 5/5 • Worth It Dosage: 7.5 mg PO once daily • Paid: $4.50/mo via Cost Plus Drugs
Mild epigastric fullness

Switched to Cost Plus Drugs at 7.5 mg PO once daily for Meloxicam; monthly out-of-pocket dropped to $4.50 compared with $19.00 retail.

Effectiveness: 5/5 • Worth It Dosage: 15 mg PO once daily max • Paid: $4.79/mo via Cost Plus Drugs

Completed 10 weeks on Meloxicam (15 mg PO once daily max). Zero notable side effects on steady dosing.

Effectiveness: 4/5 • Worth It Dosage: 7.5 mg PO once daily • Paid: $5.45/mo via Local Pharmacy
Mild epigastric fullness

Consistent biomarker response on 7.5 mg PO once daily Meloxicam sourced via Local Pharmacy ($5.45/mo cash pay without insurance prior authorization).